Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Octapharma launches phase III superiority study of Panzyga in PANS

Sep. 7, 2020

Auris advances phase II trial of intranasal betahistine for vertigo

Sep. 4, 2020

Two gut bacteria combine to exacerbate MS symptoms

Sep. 4, 2020

Spanish researchers identify new SFRP1-targeting antibodies for Alzheimer's disease

Sep. 4, 2020

FDA accepts IND for ABP-450 as a treatment for cervical dystonia

Sep. 4, 2020

'Undruggable' phosphatase can be targeted for dystrophies

Sep. 4, 2020

PTC Therapeutics discovers new compounds targeting mRNA splicing machinery

Sep. 3, 2020

Researchers from Czech Republic present compounds for neurodegeneration

Sep. 3, 2020

DE Shaw Research patents Abeta aggregation inhibitors

Sep. 3, 2020

New phase III trial explores felbinac trometamol for postoperative pain in China

Sep. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...